Low-grade inflammation is characteristic of a subgroup of currently depressed patients with major depressive disorder (dMDD). It may lead to the activation of the kynurenine-metabolic pathway and the increased synthesis of potentially neurotoxic metabolites such as 3-hydroxykynurenine (3HK) and quinolinic acid (QA), relative to kynurenic acid (KynA). Nevertheless, few studies have examined whether abnormalities in this pathway are present in remitted patients with MDD (rMDD). Here we compared the serum concentrations of kynurenine metabolites, measured using high performance liquid chromatography with tandem mass spectrometry, across 49 unmedicated subjects meeting DSM-IV-TR criteria for MDD, 21 unmedicated subjects meeting DSM-IV-TR criteria for rMDD, and 58 healthy controls (HCs). There was no significant group difference in the concentrations of the individual kynurenine metabolites, however both the dMDD group and the rMDD group showed a reduction in KynA/QA, compared with the HCs. Further, there was an inverse correlation between KynA/QA and anhedonia in the dMDD group, while in the rMDD group, there was a negative correlation between lifetime number of depressive episodes and KynA/QA as well as a positive correlation between the number of months in remission and KynA/QA. Our results raise the possibility that a persistent abnormality exists within the kynurenine metabolic pathway in MDD that conceivably may worsen with additional depressive episodes. The question of whether persistent abnormalities in kynurenine metabolism predispose to depression and/or relapse in remitted individuals remains unresolved.
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Introduction
Circulating biomarkers of inflammation such as C-reactive protein (CRP) and pro-inflammatory cytokines such as IL-1b and IL-6 have been reported to be elevated in individuals with major depressive disorder (MDD) (Howren et al., 2009 ). Cytokines and other inflammatory molecules may directly affect neurophysiological function, mood, and emotion (Miller et al., 2013) . However, inflammation may also affect mood and behavior indirectly by activating the tryptophan degrading enzyme, indoleamine 2,3 dioxygenase (IDO), increasing the formation of neuroactive kynurenine-pathway metabolites, including kynurenic acid (KynA), 3-hydroxykynurenine (3HK), and quinolinic acid (QA) (Dantzer et al., 2011) .
Kynurenine is metabolized along two main branches to form either KynA or alternatively, 3HK, 3-hydroxyanthrallic acid (3-HAA), and QA (Fig. S1 ). Both the preclinical literature and human studies of known inflammatory and/or neurodegenerative disorders have led to the hypothesis that microglial-derived 3HK and QA are neurotoxic while astrocyte-derived KynA is neuroprotective (Amaral et al., 2013; Myint and Kim, 2003; Stone et al., 2012) . While this model is likely overly simplistic, our previous
